Table 3 Risk factors for post-transplant SOS
From: Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
Risk factor | SOS (N = 11) | No SOS (N = 10) |
|---|---|---|
Median age in years (range) | 12 (2–19) | 12.5 (7–19) |
Median doses of InO (range) | 6 (3–12) | 4.5 (3–6) |
Median days from InO to HSCT (range) | 25 (13–91) | 30 (13–89) |
One or more HSCT prior to InO | 6 (55%) | 3 (30%) |
Dual alkylator conditioning | 6 (44%) | 7 (54%)a |
Busulfan containing conditioning | 5 (45%) | 1 (11%)a |
Clofarabine containing conditioning | 3 (27%) | 1 (11%)a |
TBI conditioning | 9 (82%) | 6 (60%)a |
